Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies
Rodney Varner, CEO of Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today commended The U.S. Food and Drug Administration’s (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases. As such, the FDA announced that it will support using biomarkers as substitutes for other biological indicators in gene therapy clinical trials, accelerating the approval process for companies.
“The FDA’s efforts to streamline the regulatory process will help bring much needed therapies to patients more efficiently,” commented Rodney Varner, Chairman, President and Chief Executive Officer of Genprex.
“This is a positive development for Genprex as we continue to advance our pipeline of gene therapies for patients with limited treatment options. This decision by the FDA also underscores the potential role of gene therapy to provide long-lasting and even curative treatments for diseases that are currently difficult to manage or are untreatable.”
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more